Growth of P511 mastocytoma cells in BALB/c mouse brain elicits CTL response without tumor elimination: a new tumor model for regional central nervous system immunity

• Published in: The Journal of immunology (1950) Vol. 159; no. 5; pp. 2399 - 2408
• Main Authors: Gordon, LB, Nolan, SC, Cserr, HF, Knopf, PM, Harling-Berg, CJ
• Format: Journal Article
• Language: English
• Published: United States Am Assoc Immnol 01.09.1997
• Subjects: Animals; Brain - immunology; Brain - pathology; Brain Neoplasms - immunology; Brain Neoplasms - pathology; CD3 Complex - analysis; Chemotaxis, Leukocyte; Female; Graft Rejection - immunology; Histocompatibility; Injections, Subcutaneous; Lymphocyte Subsets - immunology; Lymphocytes, Tumor-Infiltrating - immunology; Lymphoid Tissue - pathology; Mast-Cell Sarcoma - pathology; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Neoplasm Transplantation - immunology; Splenectomy; T-Lymphocytes, Cytotoxic - immunology; Transplantation, Heterotopic; Tumor Cells, Cultured
• ISSN: 0022-1767; 1550-6606
• DOI: 10.4049/jimmunol.159.5.2399

We have developed a murine model to explore the tumor-specific CTL response in the immune-privileged central nervous system using P511 mastocytoma cells. Three strains with varying degrees of histocompatibility to P511 cells (CD-1, allogeneic; BALB/c, minor histoincompatible; DBA/2, syngeneic) received tumor cells (10(4)) into the putamen 7 days after cannula implantation, when the blood-brain barrier was functionally intact. Without exception, tumor formed reproducibly by day 7 in all strains. Tumor rejection occurred in CD-1 but not in BALB/c and DBA/2 mice. Using a flank injection site, both CD-1 and BALB/c, but not DBA/2 mice, ultimately rejected flank tumors. Analysis of tumor-specific CTL in BALB/c spleens revealed that P511 administration into brain or flank elicited similar responses: no fully activated CTL were detectable but a significantly expanded population of nonkilling precursors of CTL (pCTL) were present. A P511 cell-specific pCTL population was also identified at the brain tumor site 14 days post-tumor introduction, indicating that pCTL, generated in the periphery, traffic to the tumor site in brain. These data indicate that failure to reject tumor in brain is neither due to lack of afferent stimulation nor to inability of peripheral effectors (P511 cell-specific pCTL) to reach the tumor site. We hypothesize that these effector cells are prevented from developing into fully activated CTL by conditions within the central nervous system microenvironment that down-regulate CTL development.